コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 , exhibited lower affinities for recombinant squalene synthase.
2 potencies as inhibitors of recombinant yeast squalene synthase.
3 ctivity against Ras farnesyl transferase and squalene synthase.
4 in isoprenylation that are not inhibitors of squalene synthase.
5 not nSREBP-1a, to activate the promoter for squalene synthase.
6 eductase, farnesyl diphosphate synthase, and squalene synthase.
7 eling of bisphosphonate molecules binding to squalene synthase.
8 nate molecules that were designed to inhibit squalene synthase.
12 l CoA (HMG CoA) synthase, HMG CoA reductase, squalene synthase, acetyl-CoA carboxylase, fatty acid sy
17 nes, less robust associations were found for squalene synthase and change in total cholesterol, apoli
18 that a botryococcene synthase would resemble squalene synthase and hence isolated squalene synthase-l
19 olesterol synthesis genes HMG CoA reductase, squalene synthase, and FPP synthase but did not alter le
20 f farnesyl-diphosphate farnesyl transferase (squalene synthase), but not 3-hydroxy-3-methylglutaryl-C
24 the crystal structures of recombinant human squalene synthase complexed with several different inhib
25 key amino acid residues that can convert the squalene synthase enzyme into peplusol synthase and vice
27 anosterol 14alpha-demethylase (CYP51A1), and squalene synthase (farnesyl diphosphate farnesyl transfe
28 yl-CoA carboxylase, stearoyl-CoA desaturase, squalene synthase, farnesyl-pyrophosphate synthase, 3-hy
34 tion of zaragozic acid--a known inhibitor of squalene synthases--impaired biofilm formation and prote
35 aryl-CoA reductase, fatty-acid synthase, and squalene synthase in livers of Zetia/lovastatin-treated
36 farnesyl diphosphate with recombinant yeast squalene synthase in the absence of NADPH gives a mixtur
39 f rat hepatocytes as a direct consequence of squalene synthase inhibition, we investigated possible u
42 A reductase inhibitor lovastatin and by the squalene synthase inhibitor zaragozic acid A and was pre
44 sterol biosynthetic pathway: squalestatin 1 (squalene synthase inhibitor), (E)N-ethyl-N-(6,6-dimethyl
46 tures with SQ-34919, a structurally distinct squalene synthase inhibitor, produced the same selective
49 ment with multiple statins, bisphosphonates, squalene synthase inhibitors, and small interfering RNA
50 ted a much improved in vitro antioxidant and squalene synthase inhibitory activity (at lower micromol
52 of PSPP or a prior conformational change in squalene synthase is the rate-limiting step for synthesi
53 nthase, farnesyl pyrophosphate synthase, and squalene synthase, key enzymes for cholesterol synthesis
54 ubation of [(14)C]FDP with recombinant human squalene synthase led to [(14)C]PSDP and [(14)C]squalene
55 l squalene synthase, none of the other three squalene synthase-like (SSL) genes encodes for botryococ
56 esemble squalene synthase and hence isolated squalene synthase-like genes from Botryococcus braunii r
57 treatment with bisphosphonates that inhibit squalene synthase might help protect tissues against pat
58 4S-hydroxycholesterol, HMG CoA reductase and squalene synthase mRNA levels were significantly decreas
59 B. braunii does harbor at least one typical squalene synthase, none of the other three squalene synt
60 hen co-expressed in yeast with complementary squalene synthase or botryococcene synthase expression c
61 tores are reduced secondary to inhibition of squalene synthase or LDL receptor degradation is disrupt
62 se farnesyl diphosphate synthase rather than squalene synthase or phytoene synthase, which catalyze c
63 conversion to squalene through the action of squalene synthase represents the first committed step in
69 in which antioxidant, anti-inflammatory, and squalene synthase (SQS) inhibitory/hypolipidemic activit
72 vels, signal peptide peptidase (SPP) cleaves squalene synthase (SQS), an enzyme that defines the bran
73 he activity of these compounds against human squalene synthase (SQS), as a counterscreen, finding sev
78 ly enzymes of triterpene aglycone formation: squalene synthase (SS), squalene epoxidase (SE), and bet
80 n to inhibit cholesterol biosynthesis at the squalene synthase step, may afford a novel series of hyp
81 e-specific manner, whereas the expression of squalene synthase, sterol response element-binding prote
83 doned drug lapaquistat, an inhibitor of host squalene synthase that shifts the redox environment, blo
84 t with squalestatin 1, a potent inhibitor of squalene synthase, the first committed enzyme of sterol
85 of cholesterol biosynthesis is catalyzed by squalene synthase, we explored whether inhibiting this e